Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

R 107 - Radikal Therapeutics

Next Previous
X
Search
Drug Profile

R 107 - Radikal Therapeutics

Alternative Names: R-107; R107 - Radikal Therapeutics

Latest Information Update: 28 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Radikal Therapeutics
  • Developer Claritas Pharmaceuticals; Radikal Therapeutics
  • Class Anti-infectives; Antivirals; Small molecules
  • Mechanism of Action Androgen receptor antagonists; Angiogenesis inducing agents; Cell death stimulants; Guanylate cyclase stimulants; Nitric oxide donors; Reactive oxygen species modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Pulmonary arterial hypertension

Highest Development Phases

  • Phase I Pulmonary arterial hypertension
  • Preclinical SARS-CoV-2 sepsis; Viral infections
  • No development reported Acute lung injury; COVID 2019 infections; COVID-19 pneumonia

Most Recent Events

  • 28 Aug 2024 No recent reports of development identified for clinical-Phase-Unknown development in COVID-19 pneumonia in United Kingdom (IM)
  • 28 Jun 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in USA (IM, Injection)
  • 28 Aug 2022 No recent reports of development identified for preclinical development in Acute-lung-injury in USA (IM, Injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top